Literature DB >> 21110875

Evaluation of rK-39 strip test using urine for diagnosis of visceral leishmaniasis in an endemic area in Bangladesh.

Md Gulam Musawwir Khan1, Mohammad Shafiul Alam, Milka Patracia Podder, Makoto Itoh, Kazi M Jamil, Rashidul Haque, Yukiko Wagatsuma.   

Abstract

Diagnosis of visceral leishmaniasis (VL) by demonstration of parasites in tissue smears obtained from bone marrow, spleen or lymph nodes is risky, painful, and difficult. The rK-39 strip test is widely used for the diagnosis of VL using blood/serum samples in endemic countries. The aim of the study was to evaluate the rK-39 strip test using urine sample as a non-invasive means for the diagnosis of VL. The rk-39 strip test was performed using urine from 100 suspected VL cases along with 25 disease control (malarial febrile cases) and 50 healthy control (from endemic and non-endemic areas). All the VL suspected cases were positive with the rK-39 strip test using serum. The sensitivity and specificity of the rK-39 strip test using urine samples was 95% and 93.3%, respectively, compared to serum based rK-39 test. The findings suggest that the urine based rK-39 test could be a practical and efficient tool for the diagnosis of VL patients in rural areas, particularly where resources are limited.

Entities:  

Year:  2010        PMID: 21110875      PMCID: PMC3003646          DOI: 10.1186/1756-3305-3-114

Source DB:  PubMed          Journal:  Parasit Vectors        ISSN: 1756-3305            Impact factor:   3.876


Introduction

Visceral leishmaniasis (VL) is a serious public health problem in Bangladesh where 20 million people (18% of the total population) are at risk with a trend of rising incidence [1]. Diagnosis of VL still relies on clinical manifestations and microscopic confirmation of parasites from aspirates of lymph nodes, bone marrow, and the spleen. These invasive and painful techniques require skilled personnel and are difficult to implement in resource-limited settings. Several less-invasive serological tests, including indirect fluorescent antibody test (IFAT), enzyme-linked immunosorbent assay (ELISA), and an improved version of direct agglutination test (DAT) have been evaluated for the diagnosis of VL [2-4]. However, a rapid immune-chromatographic test (ICT) based on a recombinant 39-amino acid repeat antigen, conserved in the kinesin region of Leishmania chagasi and Leishmania donovani (rK-39 strip test), gained popularity for the field screening of kala-azar [5]. The detection of soluble antigen and antibody in urine of VL patients has been reported [6]. A urine-based ELISA method has also been developed to detect anti-Leishmania donovani immunoglobulin G (IgG) [7]. Recently, a low molecular weight, heat-stable, and carbohydrate based leishmanial antigen has also been detected in urine of VL patients [8]. A latex agglutination test (KAtex) based on antigen detection in urine of VL cases has been evaluated in different field studies; however, the test showed lower sensitivity in some studies [9,10]. So, the antibody detection tests especially DAT and rK-39 strip test, are still being extensively used in the field-screening of VL. The study was conducted to determine the potential application of the rK-39 strip test for detecting anti-leishmanial antibody in urine for the preliminary diagnosis of VL infection compared with the serum-based rK-39 test to establish the value of the urine-based rapid test for the primary diagnosis of VL.

Study area and population

In total, 100 suspected VL patients, who were positive with the serum based rK-39 strip test and had fever for at least two weeks, along with other clinical signs [11], were enrolled in this study from Trishal Upazila (sub-district) Health Complex (UHC) in Mymensingh district, which is one of the most endemic VL regions in Bangladesh. All the VL subjects were treated free of charge in the UHC as per the National Guideline and the WHO recommendations. To investigate cross-reaction with other diseases, twenty five (25) subjects with malaria were enrolled from a malaria-endemic area. To investigate subclinical infection, twenty five (25) healthy controls were enrolled who lived in the endemic area (Trishal) but did not have a past history of VL. Twenty five (25) healthy controls from non-endemic area were also enrolled for assessing the specificity of the urine rK-39 strip test. The serum rK-39 test was performed again in the field setting, a small laboratory in Trishal with that is near about 300 meters form UHC, whereas the urine rK-39 test was performed in the Parasitology Laboratory, ICDDR,B in Dhaka.

Ethical approval

The Ethical Review Committee (ERC) and Research Review Committee (RRC) of ICDDR,B approved the study.

Sample collection and methods

Finger- prick blood was taken in a capillary tube and transferred to a micro-tube (200 μm). Urine samples were also collected in a tube containing preservative (Na-azide) and stored at 4°C until transporting to the ICDDR,B. The blood sample was then centrifuged for separation of serum at the field laboratory (Trishal) where the rK-39 strip test (Kalaazar Detect™, InBios Inc., USA) was also performed as per the protocol of the manufacturer. Briefly, 1 drop of serum samples was applied to the base of nitro-cellulose strips impregnated with recombinant rK-39 antigen. After being air-dried, 3 drops of the test buffer (phosphate-buffered saline, plus bovine serum albumin) were added, and the strip was placed upright. The appearance of a lower red band (control) indicated the proper functioning of the test while the appearance of an upper red band indicated the presence of anti-rK-39 IgG, signifying a positive test. For urine assay, 3 drops of urine sample were applied directly to the strip without adding any test buffer. In both the cases the strip was observed after 10 minutes for the test band. A skilled laboratory technician performed the urine rK-39 strip test in the Parasitology Laboratory ICDDR,B who also monitored the serum rK-39 strip test at the field level.

Data analysis

Sensitivity and specificity were computed along with 95% confidence interval (CI) using the Epi Info software (version 6.02; CDC, Atlanta, GA, USA). Data were also analyzed by 2×2 contingency tables using the SPSS software (version 10.0) for Windows (release 10.0.1, standard version, 1999; SPSS Inc., Chicago, USA), which enabled us to calculate the kappa coefficient or κ value. Reproducibility was assessed between the field rK-39 serum test and the urine rK-39 test in laboratory settings followed by Landis Koch [12] based on κ value.

Results

The serum rK-39 strip test was positive in 100 enrolled VL subjects whereas all the healthy controls from the endemic area and non-endemic area and all the diseased controls (confirmed malaria subjects) were tested negative. The urine rK-39 strip test was positive in 95 out of the 100 VL subjects and in five out of 25 confirmed malaria patients who were tested negative in serum rK-39 strip test. However, the urine rK-39 was tested negative in all the healthy controls from the VL endemic and non-endemic areas. Thus, the sensitivity and specificity of urine rK-39 was found 95% (95% CI: 88.2-98.1) and 93.3% (95% CI: 84.5-97.5), respectively, considering the serum rK-39 test result as the gold standard (Table 1). Kappa coefficient (κ) for the urine rK-39 strip test was found 0.88.
Table 1

Comparison of urine and Serum based rK-39 strip test in the diagnosis of clinically suspected VL

Patient typeSerum rK-39 testUrine rK-39 test

+ve-ve+ve-ve
No. of VL case1000955

No. of Malaria025520

No. of Non endemic healthy control025025

No. of VL Endemic healthy control025025

Total1007510075

Urine rK-39 strip sensitivity: 95% (95% CI: 88.2-98.1); specificity: 93.3% (95% CI: 84.5-97.5); kappa (κ): 0.88

Comparison of urine and Serum based rK-39 strip test in the diagnosis of clinically suspected VL Urine rK-39 strip sensitivity: 95% (95% CI: 88.2-98.1); specificity: 93.3% (95% CI: 84.5-97.5); kappa (κ): 0.88

Discussion

According to the national guideline for the treatment of VL in Bangladesh, suspected kala-azar cases must be confirmed by a positive rK-39 or demonstration of parasite in the tissue (bone marrow/splenic puncture) or by PCR [11]. The ICT based rK-39 antibody test has been used widely in Bangladesh for the diagnosis of VL because of its high sensitivity and specificity [5]. According to the instruction of the manufacturer, this test is performed using serum or plasma for which collection of venous blood or figure- prick is necessary. But our study showed an excellent sensitivity and specificity level for the rK-39 dipstick test using a non-invasive procedure, i.e. urine samples. The sensitivity of the urine rK-39 strip test observed in our study (95%) corroborates the results of the urine-based DAT (90.7%) and urine ELISA (93.3%) [7]. The sensitivity and specificity of urine rK-39 in our study is within the acceptance level of the serum rK-39 strip test's sensitivity and specificity of specificity targeted (>90%) in the Indian subcontinent [13]. The urine-based rK-39 test has great advantages over the serum-based test because of ease of sample collection without causing any discomfort or pain to the subject. The non-invasive urine collection procedure minimizes the risk of blood-borne infections and facilitates the collection of samples from infants and children. Although, in our study a considerable number of positive test result with malaria (5/25) were noted in urine rK-39 test, but none was found in the healthy control subjects. We suspect this positive urine rK-39 strip test as false-positive as they were tested negative in the serum rk-39 test in the same malaria patient. This kind of false positivity might be raised due to the binding of unknown urinary components with the rK-39 antigen line in the test strip. According to Boelaert et al. [14], an ideal VL rapid diagnostic test should achieve a sensitivity level of ≥95% and a specificity level of ≥98% in both field and laboratory settings, and the test results should be interpreted in 30 minutes. The findings of our study showed that the non-invasive urine rK-39 strip test gave results in 10 minutes. The sensitivity of our test was satisfactory; however desired specificity was not achieved. The reproducibility of the urine rK-39 strip test was excellent (κ = 0.88) which corroborates with the reproducibility that had been assessed in a multi-centre evaluation of rK39 strip test with serum conducted in East Africa and the Indian subcontinent [13]. In our study the specificity has probably been overestimated because under real-life conditions there will be many malaria patients among the suspects to be tested. Moreover, half of the healthy controls were from a non-endemic area. The sensitivity may have been over-estimated in our study because the comparison was based on rK-39 sero-positive subjects. Another limitation of the rK-39 test is its variable sensitivity and specificity reported in different studies [15-18]. To overcome these limitations, further investigations are required to assess the performance of the urine rK-39 test in a larger field condition with a larger population size, including parasitological confirmed VL subjects to confirm our data.

Conclusion

The urine rK-39 strip test would be a promising non-invasive point-of-care tool for the rapid screening of VL in remote rural areas where there is a high prevalence of VL. However, a large scale field evaluation of the urine rK-39 strip test is required before using it as a diagnostic tool for VL patients in different endemic areas. To the best of our knowledge, this is the first study on rK-39 strip test using urine samples.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MGMK, MSA, MI, KMJ, RH, and YW have equally contributed in designing the study protocol. MSA was the PI of the project and was responsible for field set up and enrolling patients. MGMK, MSA, and MPP performed laboratory evaluation of the test. MGMK, MSA, and MPP drafted the manuscript. All authors edited, read, and approved the final manuscript.
  16 in total

1.  Latex agglutination test for the detection of urinary antigens in visceral leishmaniasis.

Authors:  Z J Attar; M L Chance; S el-Safi; J Carney; A Azazy; M El-Hadi; C Dourado; M Hommel
Journal:  Acta Trop       Date:  2001-01-15       Impact factor: 3.112

2.  Evaluation of a urinary antigen-based latex agglutination test in the diagnosis of kala-azar in eastern Nepal.

Authors:  S Rijal; M Boelaert; S Regmi; B M S Karki; D Jacquet; R Singh; M L Chance; F Chappuis; M Hommel; P Desjeux; P Van der Stuyft; D Le Ray; S Koirala
Journal:  Trop Med Int Health       Date:  2004-06       Impact factor: 2.622

3.  A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis.

Authors:  Marleen Boelaert; Suman Rijal; Sudhir Regmi; Rupa Singh; Balmansingh Karki; Diane Jacquet; François Chappuis; Lenea Campino; Philippe Desjeux; Dominique Le Ray; Shekhar Koirala; Patrick Van der Stuyft
Journal:  Am J Trop Med Hyg       Date:  2004-01       Impact factor: 2.345

4.  Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent.

Authors:  M Boelaert; S El-Safi; A Hailu; M Mukhtar; S Rijal; S Sundar; M Wasunna; A Aseffa; J Mbui; J Menten; P Desjeux; R W Peeling
Journal:  Trans R Soc Trop Med Hyg       Date:  2007-10-22       Impact factor: 2.184

5.  Detection of Leishmania donovani soluble antigen and antibody in the urine of visceral leishmaniasis patients.

Authors:  J Kohanteb; S M Ardehali; H R Rezai
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

6.  Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen.

Authors:  Sarman Singh; Veena Kumari; Niti Singh
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

7.  rK39 enzyme-linked immunosorbent assay for diagnosis of Leishmania donovani infection.

Authors:  E E Zijlstra; N S Daifalla; P A Kager; E A Khalil; A M El-Hassan; S G Reed; H W Ghalib
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

8.  Evaluation of direct agglutination test, rk39 Test, and ELISA for the diagnosis of visceral leishmaniasis.

Authors:  Jharna Mandal; Sumeeta Khurana; M L Dubey; Prateek Bhatia; Neelam Varma; Nancy Malla
Journal:  Am J Trop Med Hyg       Date:  2008-07       Impact factor: 2.345

9.  Leish-KIT, a stable direct agglutination test based on freeze-dried antigen for serodiagnosis of visceral leishmaniasis.

Authors:  S E Meredith; N C Kroon; E Sondorp; J Seaman; M G Goris; C W van Ingen; H Oosting; G J Schoone; W J Terpstra; L Oskam
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

10.  An indirect fluorescent antibody (IFA) test for the serodiagnosis of Kala-Azar.

Authors:  A Choudhry; A Puri; P Y Guru; R P Saxena; K C Saxena
Journal:  J Commun Dis       Date:  1992-03
View more
  13 in total

1.  Evaluation of rK-39 strip test using urine for diagnosis of visceral leishmaniasis in an endemic region of India.

Authors:  Dharmendra Singh; Krishna Pandey; Vidya Nand Rabi Das; Sushmita Das; Neena Verma; Alok Ranjan; Sekhar Chandra Lal; Kamal Roshan Topno; Shubhankar Kumar Singh; Rakesh Bihari Verma; Ashish Kumar; Abul Hasan Sardar; Bidyut Purkait; Pradeep Das
Journal:  Am J Trop Med Hyg       Date:  2012-11-13       Impact factor: 2.345

2.  Peripheral blood buffy coat smear: a promising tool for diagnosis of visceral leishmaniasis.

Authors:  M Abdus Salam; M Gulam Musawwir Khan; Khondaker Rifat Hasan Bhaskar; Mokibul Hassan Afrad; M Mamun Huda; Dinesh Mondal
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

3.  Evaluation of rk39 immunochromatographic test with urine for diagnosis of visceral leishmaniasis.

Authors:  Jaya Chakravarty; Subodh Kumar; Rajiv Kumar; Shalini Gautam; Madhukar Rai; Shyam Sundar
Journal:  Trans R Soc Trop Med Hyg       Date:  2011-06-25       Impact factor: 2.184

Review 4.  Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease.

Authors:  Marleen Boelaert; Kristien Verdonck; Joris Menten; Temmy Sunyoto; Johan van Griensven; Francois Chappuis; Suman Rijal
Journal:  Cochrane Database Syst Rev       Date:  2014-06-20

5.  Evaluation of Cysteine Protease C of Leishmania donovani in Comparison with Glycoprotein 63 and Elongation Factor 1α for Diagnosis of Human Visceral Leishmaniasis and for Posttreatment Follow-Up Response.

Authors:  Nicky Didwania; Sarfaraz Ahmad Ejazi; Rudra Chhajer; Abdus Sabur; Saumyabrata Mazumder; Mohd Kamran; Raunak Kar; Krishna Pandey; Vidya Nand Ravi Das; Pradeep Das; Mehebubar Rahaman; Rama Prosad Goswami; Nahid Ali
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

6.  Short communication: evaluation of a new rapid diagnostic test for quality assurance by kala azar elimination programme in bangladesh.

Authors:  Md Gulam Musawwir Khan; Mohammad Shafiul Alam; Abu Toha Bhuiyan; Maleka Arjumand Jamil; Bijoy Saha; Mazharul Islam; Rashidul Haque; Moazzem Hossain; Kazi M Jamil
Journal:  J Parasitol Res       Date:  2011-11-02

7.  Comparative in-silico genome analysis of Leishmania (Leishmania) donovani: A step towards its species specificity.

Authors:  Satheesh Kumar S; Gokulasuriyan R K; Monidipa Ghosh
Journal:  Meta Gene       Date:  2014-10-24

8.  Diagnostic accuracy of loop-mediated isothermal amplification (LAMP) for detection of Leishmania DNA in buffy coat from visceral leishmaniasis patients.

Authors:  Md Gulam Musawwir Khan; Khondaker Rifat Hasan Bhaskar; Md Abdus Salam; Tania Akther; Gerd Pluschke; Dinesh Mondal
Journal:  Parasit Vectors       Date:  2012-12-03       Impact factor: 3.876

9.  A Comparative Study of Serum, Urine and Saliva Using rk39 Strip for the Diagnosis of Visceral Leishmaniasis.

Authors:  Sarita Mohapatra; Jyotish C Samantaray; Arnab Ghosh
Journal:  J Arthropod Borne Dis       Date:  2015-06-27       Impact factor: 1.198

Review 10.  Developments in Diagnosis of Visceral Leishmaniasis in the Elimination Era.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  J Parasitol Res       Date:  2015-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.